Aptose Upgraded to Trade on OTCQB Market
(TSX:APS),(Pinksheets:APTOF),(PinkSheets:APTOF), SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company“) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced today that the Company has been upgraded to […]